SORT BY

FILTER BY

also on other fortune lists

company facts

f500 stats

Fortune 500

Gerald Abel/Bass Photo Co.

129

Eli Lilly

LLY

The pharmaceutical giant manufactures drugs for humans as well as for livestock and poultry.

Looking for leads, investment insights, or competitive intelligence?

CEO

David A. Ricks

CEO Title

Chairman, President & Chief Executive Officer

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

Indianapolis

Years on Fortune 500 List

24

Employees

40,655

Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$22,8717.8%
Profits ($M)$-204.1-107.5%
Assets ($M)$44,981
Total Stockholder Equity ($M)$11,592
Market Value — as of March 29, 2018 ($M)$84,542
Profit Ratios
Profit as % of Revenues-0.9%
Profits as % of Assets-0.5%
Profits as % of Stockholder Equity-1.8%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)-0.19
EPS % Change (from 2016)-107.4%
EPS % Change (5 year annual rate)-
EPS % Change (10 year annual rate)-
Total Return
Total Return to Investors (2017)17.7%
Total Return to Investors (5 year, annualized)14.7%
Total Return to Investors (10 year, annualized)9.0%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Eli Lilly

Eli Lilly, AstraZeneca's Alzheimer's Drug Flop Is the Latest Disappointment in a Frustrating Disease

The story of Alzheimer's drug development is one of perpetual tragedy and setbacks.

Read More →
The Diseases We Aren't Curing—And Why

Drug makers are flocking to certain treatment types. Why do others get left behind?

Read More →
Alzheimer's Cases Are Expected to Double By 2060 and We're Not Ready for It

There still aren't any truly effective drugs for Alzheimer's or dementia.

Read More →